# A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

> **NCT02221960** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 39 (actual)

## Conditions studied

- Recurrent or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** MEDI6383
- **BIOLOGICAL:** MEDI6383 and MEDI4736

## Key facts

- **NCT ID:** NCT02221960
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-15
- **Primary completion:** 2017-07-03
- **Final completion:** 2017-07-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221960, "A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02221960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*